Goodwin Attorneys Discuss How Foreign Companies Can Break Into China’s Biosimilar Market
Huiya Wu, JD, and Freddy Yip, PhD, PCLL, attorneys at Goodwin Procter, discussed projections for the Chinese biosimilars market and the potential for foreign companies to get a share.
Canada Sees Second Adalimumab Biosimilar Launch in a Week
Fresenius Kabi steps into the Canadian market for adalimumab with Idacio.
The Top 5 Biosimilar Articles for the Week of February 15
Here are the top 5 biosimilar articles for the week of February 15, 2021.
Study: Increasing Biosimilar Use in RA Requires Greater Disease Management Knowledge
Biosimilar availability will expand treatment of rheumatoid arthritis (RA) to more patients and earlier disease settings, so it's important to understand the potential complications.
US vs China: Goodwin Attorneys Discuss Patent Hurdles and Adalimumab Marketing
Huiya Wu, JD, and Freddy Yip, PhD, PCLL, attorneys at Goodwin Procter, discussed biologic drug patent laws in China and the US.
Coherus Files Adalimumab BLA, Although Intended Concentration Is Unclear
Coherus BioSciences filed a 351(k) biologics license application (BLA) for CHS-1420, an adalimumab biosimilar candidate.
Poll: What Will Be the Strongest Trend in 2021?
Which of these selections do you think is the most powerful trend in medicine to emerge from the pandemic?
Sandoz Launches Adalimumab Biosimilar in Canada
The launch of Hyrimoz gives Sandoz 5 biosimilars on the Canadian market. National policies on switching have given biosimilars a tailwind.
Celltrion Healthcare Gains EU Authorization for High-Concentration Adalimumab
The marketing of Yuflyma is expected to give Celltrion Healthcare a significant advantage over existing adalimumab biosimilars.
Study: Gender, Internet Habits Influence Biosimilar Acceptance
Patient characteristics are predictive of whether a switch to a biosimilar is likely to be accepted, investigators found.
Not So Different: Steven Lucio Discusses BI’s Citizen Petition and the Current Status of Biosimilars
We sat down with Steven Lucio, PharmD, BCPS, senior principal of Pharmacy Solutions for Vizient, to discuss Boehringer Ingelheim's recent citizen's petition to the FDA.
Amgen Panel Tackles Lessons From Pandemic
Biosimilars, supply chain adjustments, building trust, and international standardization were discussed as means to deliver innovation when it's needed, not after.
Biocon Gains EU Authorization for Insulin Aspart Biosimilar
The Bengaluru, India, company said the fast-acting biosimilar will improve affordability of insulin in Europe, which also faces rising prices and access problems.
The Top 5 Biosimilar Articles for the Week of February 8
Here are the top 5 biosimilar articles for the week of February 8, 2021.
Lannett, HEC Pharm Team Up on Insulin Aspart Biosimilar Project
Lannett and HEC Pharm are developing an insulin aspart biosimilar on the heels of their insulin glargine codevelopment project.
DOJ Withdraws Support for ACA Strikedown
Under the Biden administration, the Department of Justice (DOJ) has reversed course and now backs the constitutionality of the Affordable Care Act (ACA).
Study: Nocebo Is Likely Cause for Reverse Switching in IBD
Three-fourths of patients who reverse-switched to originator infliximab from CT-P13 benefited, although it wasn't clear why the biosimilar treatment "failed."
Roche's 2020 Losses to Biosimilars Were "Worst It Can Get"
Biosimilar competition took a big chunk of revenue from Roche's aging blockbusters in 2020, and the company is banking on its newer medicines to drive fresh revenue growth.
Not So Different: The Race to the Top: Does China Have What It Takes?
China’s regulatory reforms and policy enhancements bode well for a thriving biosimilars industry.
Long-term Observational Study Supports Switch From Infliximab to SB2 in IBD
A long-term observational study suggests a non-medical switch from infliximab to SB2 is “a feasible option” for patients with inflammatory bowel diseases (IBD).
Celltrion Gains Canadian Nod for Subcutaneous Infliximab
Celltrion aims to try a direct marketing approach in Canada to streamline sales of its subcutaneous form of Remsima.
The Top 5 Biosimilar Articles for the Week of February 1
Here are the top 5 biosimilar articles for the week of February 1, 2021.
Amgen Profits Get a Ride on Biosimilar Growth
Amgen described how a double-edged biosimilars sword has worked for and against the company's profit margin.
Pfizer Biosimilar Revenues Top $525 Million in Fourth Quarter 2020
Pfizer's investment in biosimilars is starting to pay off, as it now ranks these agents among its top revenue drivers.
Poll: How Much Do You Know About Biosimilars in China?
Test your knowledge of biosimilar approvals in China.
Oncology Biosimilar Roundup for January 2021
Findings from biosimilar studies of Kanjinti (trastuzumab) and Mvasi and Zirabev (bevacizumab) rounded out our oncology biosimilar coverage in January.
Magellan Rx Reports Step Therapy Is Workhorse in Biosimilar Utilization
The pharmacy benefit manager reported 90% biosimilar uptake among its health plans that adopted clinical management policies that included step therapy or parity usage.
The Top 5 Biosimilar Articles From SABCS 2020
Here are the top 5 biosimilar articles from SABCS 2020.
Study: Bevacizumab Biosimilar Finds Acceptance in First-Line Treatment of mCRC
Investigators noted comparable use of bevacizumab biosimilar and reference products among patients treated for metastatic colorectal cancer (mCRC).
FDA Accepts Bio-Thera's BLA for Bevacizumab Biosimilar
Guangzhou, China-based Bio-Thera has filed a biologics license application (BLA) with the FDA for the approval of bevacizumab biosimilar candidate BAT1706.